GSACOTC

GELSTAT CORP

Technology·Neurology·Commercial·Palm City, FL, United States
NeurologyPain

GELSTAT CORP (GSAC): 2 pipeline candidates. Updated within the last hour.

7.3/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for GELSTAT CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.1M

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (2 candidates)

DrugPhase
gelstat migraineApproved
gelstat sleepPreclinical
·CEO: Mr. Javier G. Acosta

Frequently asked questions

How many drug candidates are in GELSTAT CORP's pipeline?

GELSTAT CORP (GSAC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is GELSTAT CORP's lead drug candidate?

GELSTAT CORP's most advanced tracked candidate is gelstat migraine (Approved) for acute relief from migraine and migraine-like headaches.

What is GELSTAT CORP's market capitalization?

GELSTAT CORP's market capitalization is approximately $1.1M.

Who is the CEO of GELSTAT CORP?

Mr. Javier G. Acosta is the chief executive officer of GELSTAT CORP (GSAC).

Get the full picture on GELSTAT CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar